At that time chronic viral infection (particularly measles) had been implicated in MS pathogenesis, and it was speculated that NK cell dysfunction might permit the persistence of viruses in the central nervous system (CNS), ultimately culminating in inflammatory demyelination. Since then, the hypothesis that MS lesion formation is driven by an active infection has largely been discounted in favor of an autoimmune etiology. This raises the question of whether NK cells directly modulate encephalitogenic leukocytes. In fact, targeted depletion of NK cells exacerbates experimental autoimmune encephalomyelitis (EAE). 5, 6 Ex vivo experiments demonstrate that NK cells are capable of modulating or killing myelinprimed lymph node cells, antigen-presenting cells, and pathogenic monocytes. 5, [7] [8] [9] As underscored in the commentary by Dr Laroni, an interest in NK cells as regulators of the human disease was rekindled by mechanistic substudies of MS clinical trials that revealed an association between the therapeutic efficacy of disease-modifying therapies (DMTs), or autologous hematopoietic stem cell transplantation, and the expansion of circulating NK cells. 7, [10] [11] [12] [13] Of particular interest is a CD56 bright subset of NK cells that were first found to accumulate in the blood of MS patients treated with daclizumab, and subsequently in patients treated with alemtuzumab or dimethyl fumarate. [10] [11] [12] While compelling, these studies do not definitively distinguish between whether NK cell expansion plays a causative role in MS disease suppression or represents an epiphenomenon. In fact, CD56 high NK cell journals.sagepub.com/home/msj Visit SAGE journals online journals.sagepub.com/ home/msj counts are not predictive of MS lesion accumulation beyond a year of daclizumab treatment, and daclizumab-treated patients whose CD56 bright NK cells did not expand still enjoyed some degree of therapeutic benefit. 10 A growing appreciation of the heterogeneity and functional subspecialization of NK cells cautions against making generalizations regarding the impact of diminishing or augmenting their activity in patients with MS. 14, 15 Liu et al. 16 raise the important point that relatively little is known about the behavior of NK cells within the human CNS microenvironment where they could, theoretically, damage oligodendrocytes, neurons, or their progenitors. This concern is underscored by the contribution of NK cells to perivascular cortical demyelination in a novel EAE model. 17 In addition to intrinsic differences between NK cell subsets, NK cell function may vary with MS lesion type, CNS compartment, disease stage, and genetic and environmental factors. As in other aspects of medicine, it is likely that future NK-based therapies in MS will need to be customized, and their judicious use instructed by considerably more research than currently available.
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